How we change lives
Investing in Healthcare
Investing in the resilient Health Care sector
Horizon 3 is building a portfolio we expect to deliver an IRR of 20% per annum over a 5 year timeframe. *
Investing in healthcare products that have global growth potential – medical devices, drugs, digital health and diagnostics.
* returns are not guaranteed
Backing companies with runs on the board
Growth stage healthcare companies with runs on the board – typically already have achieved clinical validation and are revenue generating.
World Class CIO
Led by one of Australia’s Leading Healthcare investors, CIO Matt McNamara, Molecular biologist
Previous funds delivered top quartile returns and backed 3 unicorns.
Horizon 3 is Matt’s 5th fund over the past 20+ years.
We invest in the long term by contributing capital, business excellence, deep commercialisation partnerships and unparalleled health science expertise.
From bright thinking to better health outcomes, and ultimately returns for our investors.
We are a powerful team made up of seasoned entrepreneurs, life science specialists and experienced investors who are experts at finding great ideas in which to invest. Our efforts are focused on selecting talented life sciences teams and companies with huge potential.
Chief Investment Officer & Board Director
Senior Investment Professional & Investment Committee Member
Life Sciences Business Development Exec & Investment Committee Member
Dr Qibing Mei
Pharmacologist & Investment Committee Member
Investment Analyst & Investment Committee Member
Assoc Prof Tam Nguyen
Non-Executive Director and Deputy Director of Research
Banking and Capital Markets Executive & Board Executive Chairman
Entrepreneur and founder of HK Biotechnology & Board Director
Robin Chambers AO
Corporate Lawyer and Advisor & Board Director
Senior Corporate Advisor & Board Director